Hua Yu

1.0k total citations · 1 hit paper
18 papers, 662 citations indexed

About

Hua Yu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hua Yu has authored 18 papers receiving a total of 662 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Hua Yu's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Genomics and Diagnostics (6 papers) and Lung Cancer Treatments and Mutations (4 papers). Hua Yu is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Genomics and Diagnostics (6 papers) and Lung Cancer Treatments and Mutations (4 papers). Hua Yu collaborates with scholars based in United States, Germany and Spain. Hua Yu's co-authors include Fernando Rivera, Meinolf Karthaus, Lee S. Schwartzberg, Gianpiero Fasola, William Y. Go, Jean-Luc Canon, Kelly S. Oliner, J. Randolph Hecht, Yanfang Xu and Timothy C. Hall and has published in prestigious journals such as Journal of Clinical Oncology, PLANT PHYSIOLOGY and Philosophical Transactions of the Royal Society B Biological Sciences.

In The Last Decade

Hua Yu

17 papers receiving 651 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 478 citations Lee S. Schwartzberg, Fernando Rivera et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Hua Yu

Since Specialization

Citations

This map shows the geographic impact of Hua Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hua Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hua Yu more than expected).

Fields of papers citing papers by Hua Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hua Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hua Yu. The network helps show where Hua Yu may publish in the future.

Co-authorship network of co-authors of Hua Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Hua Yu. A scholar is included among the top collaborators of Hua Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hua Yu. Hua Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Prevalence of RAS mutations among patients with metastatic colorectal cancer by country and region in randomized clinical trials: A pooled analysis. 2015 ·Journal of Clinical Oncology ·Marc Peeters, George Kafatos, Aliki Taylor, Victor M. Gastañaga, Hua Yu, Kelly S. Oliner, Gregory A. Maglinte, Jan-Henrik Terwey, (unknown)	1
2	PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer breakdown → 2014 ·Journal of Clinical Oncology ·Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, J. Randolph Hecht, Hua Yu, Kelly S. Oliner, William Y. Go	478
3	KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis 2014 ·Annals of Oncology ·Marc Peeters, Kelly S. Oliner, Timothy Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, A. H. Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Hua Yu, A. Scott Jung, R. Sidhu, Scott D. Patterson	2
4	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). 2014 ·Journal of Clinical Oncology ·Marc Peeters, Kelly S. Oliner, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Hua Yu, A. Scott Jung, Roger Sidhu, Scott D. Patterson	33
5	Extended RAS analysis and subsequent anti-EGFR and anti-VEGF treatment (tx) in PEAK: A first-line phase 2 study of FOLFOX6 + panitumumab (pmab) or bevacizumab (bev) in metastatic colorectal cancer (mCRC). 2014 ·Journal of Clinical Oncology ·Fernando Rivera, Lee S. Schwartzberg, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, J. Randolph Hecht, Ying Tian, Hua Yu, Kelly S. Oliner, William Y. Go	4
6	Seasonal dynamics of Schistosoma japonicum infection in buffaloes in the Poyang Lake region and suggestions on local treatment schemes 2013 ·Veterinary Parasitology ·Jinming Liu, Hua Yu, Yaojun Shi, Hao Li, Liang He, Jianxi Li, (unknown), (unknown), Yamei Jin, Lu Ke, Jiaojiao Lin	5
7	Kras/Nras Mutations in Peak: a Randomized Phase 2 Study of 1St-Line Treatment with Folfox6 + Panitumumab or Bevacizumab for Wild-Type Kras Mcrc 2013 ·Annals of Oncology ·Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, Lee S. Schwartzberg, Hua Yu, Kelly S. Oliner, William Y. Go	3
8	Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). 2013 ·Journal of Clinical Oncology ·Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, Hua Yu, Kelly S. Oliner, William Y. Go	21
9	PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild‑type (WT) KRAS metastatic colorectal cancer (mCRC). 2013 ·Journal of Clinical Oncology ·Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, Hua Yu, William Y. Go	19
10	6143 POSTER Study 20050203/PRIME – Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) 2011 ·European Journal of Cancer ·Salvatore Siena, Jean‐Yves Douillard, (unknown), Josep Tabernero, R. Burkes, Mario Barugel, Yves Humblet, David Cunningham, Hua Yu, Kartik Krishnan	1
11	A Memory-Efficient Hashing by Multi-Predicate Bloom Filters for Packet Classification 2008 ·Hua Yu, Rajarshi Mahapatra	14
12	A Memory-Efficient Hashing by Multi-Predicate Bloom Filters for Packet Classification 2008 ·2008 Proceedings IEEE INFOCOM - The 27th Conference on Computer Communications ·Hua Yu, R. Mahapatra	0
13	[Analysis of prognostic factors in patients with cervical squamous cell carcinoma of stage Ib and IIa]. 2005 ·PubMed ·(unknown), Weiguo Lü, Xing Xie, Huaizeng Chen, Hua Yu, (unknown)	2
14	Practical QoS network system with fault tolerance 2003 ·Computer Communications ·(unknown), Sajal K. Das, Hua Yu, (unknown), Giovanni Pau, Mário Gerla	5
15	Field evaluation of a test for praziquantel resistance in Schistosoma sp. 2003 ·Veterinary Parasitology ·(unknown), (unknown), (unknown), Hua Yu, Yao Shi, (unknown), G.C. Coles	17
16	[Drinking water types, microcystins and colorectal cancer]. 2000 ·PubMed ·(unknown), Dandan Yu, Hua Yu, (unknown), (unknown), (unknown), Yibing Ruan, (unknown)	20
17	Rice Triosephosphate Isomerase Gene 5[prime] Sequence Directs [beta]-Glucuronidase Activity in Transgenic Tobacco but Requires an Intron for Expression in Rice 1994 ·PLANT PHYSIOLOGY ·Yanfang Xu, Hua Yu, Timothy C. Hall	33
18	Transgene expression and agronomic improvement of rice 1993 ·Philosophical Transactions of the Royal Society B Biological Sciences ·Timothy C. Hall, Yanfang Xu, Clayton C. Huntley, Hua Yu, (unknown), (unknown), Marc Lepetit, Jiaqi Dong, Deborah Wallace, M. O. Way, Wallace G. Buchholz	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact